Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

72.01
Delayed Data
As of Jun 28
 +1.69 / +2.40%
Today’s Change
51.82
Today|||52-Week Range
75.12
+4.68%
Year-to-Date
BMY Regular Dividend: BMY will begin trading ex-dividend on 06/29/16 with a $0.38 dividend payable to shareholders of record as of 07/01/16.
Pfizer Investing $350M in China, Setting up Biotech Center
Jun 28 / Zacks.com - Paid Partner Content
New Strong Buy Stocks for June 28th
Jun 28 / Zacks.com - Paid Partner Content
5 Medical Stocks to Buy with Great Dividend Yields
Jun 28 / Zacks.com - Paid Partner Content
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Jun 27 / Zacks.com - Paid Partner Content
Cramer: Here's What's Behind the Horrible Politics of Brexit
Jun 28 / TheStreet.com - Paid Partner Content
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
Puma (PBYI) Submits Neratinib Marketing Application in EU
Jun 28 / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
GW Pharmaceuticals Stock Up on Positive Epidiolex Data
Jun 28 / Zacks.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close70.32
Today’s open70.95
Day’s range70.67 - 72.08
Volume7,066,389
Average volume (3 months)6,087,769
Market cap$117.4B
Dividend yield2.11%
Data as of 4:00pm ET, 06/28/2016

Growth & Valuation

Earnings growth (last year)-22.50%
Earnings growth (this year)+25.84%
Earnings growth (next 5 years)+21.20%
Revenue growth (last year)+4.29%
P/E ratio76.9
Price/Sales6.97
Price/Book8.19

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+1.42+3.63%
NVONovo Nordisk+1.32+2.59%
GSKGlaxoSmithKline+1.19+2.96%
ABBVAbbVie+1.31+2.23%
Data as of 4:02pm ET, 06/28/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.66
Annual revenue (last year)$16.6B
Annual profit (last year)$1.6B
Net profit margin9.45%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Giovanni Caforio
Chief Financial Officer &
Executive Vice President
Charles A. Bancroft
Corporate headquarters
New York, New York

Forecasts

Partner Offers

Search for Jobs